

ISSN : 2347 - 2243



*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com

Email : editor@iajlb.com or iajlb.editor@gmail.com



An Overview of the Use of Recovered Plasma in the Treatment and Prevention of Covid-19.

Dr. MOHD YUNOOS, Mrs. VENKATA KUMARI MUDIGONDA, Mr. M PRAVEEN

PROFESSOR¹, Associate Professor², Asst Prof³

M.PHARMACY-Pharmaceutical Analysis,¹ B.PHARMACY^{2,3}

Nimra College of Pharmacy, Jupudi, Krishna District, Andhra Pradesh-521456.

ABSTRACT: Novel coronavirus disease 2019 (COVID -19) has prompted a reevaluation of the efficacy of traditional convalescent plasma transfusion (CPT) since no particular antiviral medicines have yet been authorized for this virus. Since it has been shown that polyclonal neutralizing antibodies may shorten the duration of viremia, convalescent plasma therapy has been used to treat infectious diseases since the early 1900s. According to the facts we have, (a) is the most important result. Patients in critical care who get convalescent plasma treatment have a lower rate of death. (b). Clinical symptoms improved after receiving convalescent plasma. (c). Following CPT treatment, an increase in neutralizing antibody titers and a loss of SARS-CoV-2 RNA were seen in almost all patients. In this paper, we explore some of the Convalescent plasma therapy (CPT) for the treatment of COVID-19: an overview of its background, definition, mechanism of action, production, formulation, and therapeutic applications. Potential Risk, Risk Benefit Analysis, Optimal Dosing, Transfusion, and Convalescent Plasma.

Key-words: Analysis of risks and benefits of convalescent plasma treatment (Covid-19).

I. INTRODUCTION:

When no effective vaccine or medicine is currently on the market to treat a newly emergent infectious disease, convalescent plasma (CP) has been considered as a potential treatment alternative.[1] Rapid access to treatment alternatives is essential in the face of a spreading epidemic. Given the current pandemic of coronavirus illness (COVID-19), the use of convalescent plasma transfusions may be of excessive value due to the absence of particular prophylactic and therapeutic alternatives. Particularly intriguing is the use of convalescent plasma in treatment.

when there is no treatment or vaccination for a newly discovered virus, such as the one that causes COVID-19 (severe acute respiratory syndrome coronavirus-2). Rapid scientific partnerships to create targeted vaccines or therapeutics have historically been part of the response to emerging and re-emerging infectious diseases. In light of this, the World Health Organization (WHO) is funding a massive international study called SOLIDARITY to examine the efficacy of presently available treatments for COVID-19. These treatments include remdesivir, chloroquine and hydroxychloroquine, lopinavir and ritonavir, and lopinavir + ritonavir + interferon-beta. Furthermore, there is widespread curiosity in the potential of using convalescent plasma from cured COVID-19 patients to treat or prevent the disease in healthcare providers. In regards to researching convalescent plasma for COVID19 in the US, the US Food and Drug Administration (US FDA) has issued guidelines [2]. Positive-sense, single-strand RNA of 26–32 kilobases in length characterizes viruses of the family Coronaviridae [3]. Numerous bird species and

various mammalian species, including bats, camels, mice, cats, dogs, and most recently scaly anteaters, have been identified as hosts for coronaviruses [4,5]. Most coronaviruses are dangerous to humans, although even when they infect people, they usually only cause minor symptoms or none at all. The severe acute respiratory syndrome coronavirus (SARS-CoV) [6] and the Middle East respiratory syndrome coronavirus (MERS-CoV) [7] are two examples of viruses from this family that have emerged as major health threats in the recent two decades. A novel coronavirus related to severe pneumonia was discovered in Wuhan, China in December 2019 [8]. High fever, dyspnea, and chest radiographs showing invasive multilobed lesions [9,10] were common clinical manifestations, suggesting that patients had SARS-CoV or MERS-CoV.

SARS-CoV and MERS-CoV were shown to be related to COVID-19 in a phylogenetic study in roughly 79% and 50%, respectively. There has been recent speculation that the virus's sequence similarity to human proteins may be harmful and linked to autoimmune disorders [11,12]. It has been proposed that it would be safer to test cross-reactivity of different viral antigens with those in humans to reduce the probability of autoimmune reactions (i.e., molecular mimicry), especially in individuals with genetic background for autoimmunity [11,13], even though the current situation argues for prompt vaccination strategies. The intervention group in a recent randomized controlled study with Hydroxychloroquine had a lower core body temperature and a complete absence of coughing compared to the control group [14]. Due to the current state of knowledge on COVID-19 therapy and vaccines, traditional and historical methods of disease management have made a comeback. One such technique of passive immunization that has been employed in the prevention and treatment of infectious illnesses since the early 20th century [15] is the administration of convalescent plasma (CP).

Apheresis is used to collect CP from people who have acquired antibodies against the pathogen of interest and have survived an illness induced by that pathogen. The primary goal is to inactivate the infection so that it may be eradicated [16]. Spanish flu, SARS-CoV, West Nile virus, and most recently Ebola virus have all had CP regarded as emergency interventions because to its accessibility. [17,18]. In severe acute respiratory infections of viral origin, such as influenza and SARSCoV, early administration of CP following the beginning of symptoms was associated with a decrease in mortality compared with placebo or no therapy [17,19]. Apheresis not only collects NABs from donors but also a wide variety of other proteins, including clotting factors, natural antibodies, defensins, pentraxins, and anti-inflammatory cytokines [20]. Infected individuals who get a CP transfusion may reap additional advantages, including immunomodulation through reduced inflammatory response [21]. Over-activation of the immune system, accompanied by systemic hyper-

inflammation or a "cytokine storm" produced by IL-1, IL-2, IL-6, IL-17, IL-8, TNF, and CCL2, may be the situation with COVID-19. This inflammatory response might

increase the risk of developing pulmonary fibrosis and a decreased lung capacity [22,23].

History:

The English Physicist Sir William Crookes identified plasmas in 1879, although it was an American physicist Dr. Irving Langmuir who first applied the word Plasma to ionized gas in 1929. In the late 1850s, the Siemens company used plasma discharge to generate ozone, which acted as an agent to remove contaminant and toxin from water. Nevertheless for the next 100 years little research was conducted exploring the relationship between plasma and biological cells. From the 1960s to 1980s plasmas were mainly utilized as a secondary agent to indicate biological sterilization yet diminutive cause and effect knowledge was advanced. It was not until the mid-1990s that Scientist made considerable progress in cold plasma technology. As the news of plasma science spread visionary researchers, took notice and began to explore various ways to utilize plasmas unique properties. Plasma science was in its infancy in the 1990s but by 1947 multidisciplinary teams set out, to understand the effect that plasmas had on pathogenic and nonpathogenic micro-organisms and advance proof of concept lessons to demonstrate that plasma could be used as a decontaminant or sterilizing agent. Since the late 1990s plasma research has involved at a rapid pace as technology expanded into areas such as biochemical, environmental aerospace and the military [86, 87]

What is convalescent plasma therapy:

Convalescent plasma (CP) therapy is an intervention in which plasma collected from convalescent or recovered patients is used to treat various infectious diseases, and it has been proposed for emerging viral infections. [24] It is theorized that CP, which contains disease-specific antibodies that could neutralize the viral particles in COVID-19 patients, can be used to treat the disease. [25]. CP therapy involves transfusion of a blood product and is therefore associated with a risk of adverse events including anaphylaxis, transfusion related lung injury,

transfusion associated circulatory overload, and transmission of infections[26].

The Public Health Agency of Canada reported an overall risk of adverse events related to transfusion of blood components as 1 in 2,405 per 100,000 units transfused).[27]. To mitigate the risk of transfusion related acute lung injury due to donor-derived human leukocyte antigen (predominantly found in females who have been pregnant), male plasma donors may be preferred.[28,29]. A risk of TECHNOLOGY REVIEW Convalescent Plasma Therapy for the Treatment of COVID-19 4 antibody dependent enhancement of infection, in which antibodies to one type of coronavirus could amplify infection to another viral strain, has been theorized. [30]. A possible molecular mechanism for antibody dependent enhancement has been described in other coronaviruses like the Middle East respiratory syndrome coronavirus. [31]

Mechanism of action:

The antibodies present in immune plasma mediate their therapeutic effect through a variety of mechanisms. Antibody can bind to a given pathogen (e.g. virus), thereby neutralizing its infectivity directly, while other antibody-mediated pathways such as complement activation, antibody-dependent cellular cytotoxicity and/or phagocytosis may also contribute to its therapeutic effect. Non-neutralizing antibodies that bind to the pathogen but do not interfere with its ability to replicate in in vitro systems may also contribute to prophylaxis and/or enhance recovery [32,33]. Importantly, passive antibody administration offers the only short-term strategy to confer immediate immunity to susceptible individuals. This is particularly the case in the setting of a novel, emerging infectious disease such as SARSCoV-2/COVID-19. While fractionated plasma products (e.g. hyperimmune globulin, monoclonal antibodies) and/or vaccination may offer durable therapeutic options, human anti-SARS-CoV-2 plasma is the only therapeutic strategy that is immediately available for use to prevent and treat covid.

transfusions over the period of 2011 to 2015. Transfusion associated circulatory overload was the most common adverse transfusion reaction (18.1




Fig. no. 1. General mechanism of action, convalescent of plasma therapy.

Production and composition: Historical perspective:

In 1880, researchers discovered that animals inoculated with sublethal doses of toxins developed resistance to diphtheria, and that these antibodies could be transferred to healthy animals with active illnesses, establishing the basis for CP infusion. Then, it was realized that immune plasma does more than only destroy the pathogen; it also offers passive immunomodulatory qualities that help the receiver regulate the excessive inflammatory cascade brought on by many infectious agents or sepsis [20,35]. By the early 1950s, it was possible to treat significant viral infections and immunological problems such as primary immunodeficiencies, allergies, and

autoimmune diseases by the purification and concentration of immunoglobulins from healthy donors or recovered patients [34,36,37]. Intravenous immunoglobulins (IVIg) and polyclonal or monoclonal antibodies are two examples of the types of regenerative blood products created to treat infectious diseases [15].

However, they are time-consuming and costly to make, and they may not provide effective infection control in emergency settings. Given the paucity of effective drugs or vaccinations, CP has been frequently employed as a first therapeutic choice in many epidemics, and is typically used as a last chance or experimental therapy [20]. The use of CP has been shown to considerably lower case fatality rates, both during the Spanish flu and the current epidemic caused by SARS-Cov-2. In the cases of influenza A (H1N1) pdm09, Spanish flu, and SARS-CoV infections, CP usage was linked to lower rates of lethality and death [6,38-50]. The use of CP has also raised concerns about its safety in past outbreaks. There is now evidence that CP is safe for use in urgent conditions. The administration of CP has not been linked to any adverse events during the Influenza A (H1N1), SARS-CoV, or MERS pandemics. Mild adverse effects were seen after CP injection for Ebola, including sickness, skin erythema, and fever [19].

The use of convalescent plasma against coronaviruses:

Two further coronavirus outbreaks in the 21st century have made use of convalescent plasma: SARS1 in 2003 and MERS in 2012 to the present. Convalescent plasma has been shown to contain neutralizing antibodies [51] based on lessons learned from previous outbreaks. Eighty patients in Hong Kong were treated for SARS1 in the biggest study [52]. Patients who were treated with plasma before day 14 fared better than those who were given plasma after day 14, as measured by early hospital release (before day 22). Three patients with SARS-CoV-1 infection in Taiwan were treated with convalescent plasma, leading to a drop in viral load, and all three recipients lived [53]. This limited data demonstrated benefit in critically sick persons. Three patients with MERS in South Korea were treated with convalescent plasma, according to reports [54]. Convalescent plasma treatment for MERS patients was

hampered by an insufficient number of donors with high enough antibody levels [55]. There is a great deal of discrepancy between reported doses and the characterisation of convalescent plasma (i.e., with regard to antibody titers). There have been reports of the use of convalescent plasma in the treatment of patients with COVID19 in China during the current pandemic [56, 57]. Transfusion of convalescent plasma resulted in no serious adverse effect in the recipients. All 10 patients had improvement in symptoms (e.g. fever, cough, shortness of breath and chest pain) within 1-3 days of transfusion; they also demonstrated radiological improvement in pulmonary lesions. In 7 RNA-emic patients, transfusion of convalescent plasma was temporally associated with undetectable viral loads. Further, screening of 39 of 40 (97.5%) of recovered COVID-19 patients displayed neutralizing antibody titers ≥ 160 . A case series of 5 critically ill patents in China also reported improvement in clinical status following transfusion with convalescent plasma (SARS-CoV-2 IgG titers > 1000) as evidenced by weaning off mechanical ventilation, reduction in viral loads, improved oxygenation and clinical stabilization [57]. Although constrained by small sample sizes and 5 limitations of study design and concomitant treatment modalities (e.g. ribavirin, corticosteroids, etc.) these findings advise that administration of convalescent plasma is safe, reduces viral load and may improve clinical outcomes. Such has led to calls for the wider adoption of convalescent plasma for COVID-19 [58]. Nonetheless, while the data support safety and potential efficiency of convalescent plasma, randomized trials are needed [58]. Similarly, high-dose intravenous immune globulin (IVIg) has been suggested as a potential therapy for COVID-19 [59].

Convalescent plasma collections workflow:

Convalescent plasma can be prepared rapidly using the recognized blood collection and transfusion infrastructure.

Specifically, convalescent plasma is obtained and administered using standard collection and transfusion practices that are available around the world.




Fig. no. 2. Convalescent plasma collections workflow. EUA, Emergency Use Authorization; TTI, transfusion-transmitted infection.

Donor recruitment:

Those who have recovered from COVID-19 will be recruited to serve as potential blood donors. Given the magnitude of the pandemic, finding donors is not anticipated to be a problem. Approaches include community outreach in areas with robust epidemics, advertising and communication through media, and/or directly through providers (e.g. at time of discharge) and their professional organizations (e.g. databases, websites—<https://ccpp19.org>). There is also consideration about messaging those

who receive positive results either prospectively or after the fact? The latter postures some decent concerns, which weigh public health need against patient privacy and confidentiality. A limited waiver of HIPAA in the US may allow for greater freedom in this regard. [60].

Antibody testing:

The FDA recommendations reflect the difficulties inherent in antibody testing. In general, unreliable diagnostic tools cannot be used in donor selection or in the production of a therapeutic substance. However, there is debate about which antibodies work best against COVID-19.

Functionality is more likely to be correlated with neutralizing antibodies. However,

There is a lack of accessibility and a lack of high throughput screening options for neutralizing antibody tests in clinical labs. While quantitative tests (such as ELISA) do exist, those on the market have not undergone extensive validation. It is also not apparent what role neutralizing antibodies play in respect to total anti-SARS-CoV-2 antibodies. Whether total antibodies or subclasses (e.g. IgM, IgG, or IgA) are the ideal measure and which antigen is most informative is also debatable [61,62]. Several variants of the spike or S protein have been utilized in these experiments. There is a lack of information on the ELISAs at the moment. One study showed "strong reactivity against IgG3, IgM, and IgA" when testing for spike antigens, while also showing "low cross-reactivity when testing other human coronaviruses" [19].

A point-of-care antibody test for simultaneous IgM and IgG detection was reported to have 88.7 percent sensitivity and 90.6 percent specificity by another group [63]. When samples are taken in relation to the commencement of infection, it affects the antibody titer. Although research is sparse, seroconversion has been found anywhere from 8 days to 21 days after symptoms first appear [62,64]. Findings show that units of plasma obtained 14 days after resolution of symptoms should have high titers of antibodies [65], which is consistent with reports from China of high titers of anti-SARS-CoV-2 antibodies in the overwhelming majority of convalescent patients.

One must strike a balance between urgency of need and the need for a thoroughly validated test and a refined treatment technique in the context of a temporizing therapy. The FDA controls this ambiguity by proposing testing instead of demanding it (i.e., defined SARS-CoV-2 neutralizing antibody titers, ideally more than 1:320)[66].

Optimal dosing and transfusion:

Changes in indication (i.e., prevention vs therapy) may account for the substantial variability in convalescent plasma dosage over time. Relevant to the present epidemic, a research was conducted in China using a single plasma unit (200 mL) [66]. One unit is considered for post-exposure prophylaxis and one to two units are proposed for treatment in the planned clinical studies. The antibodies' supposed long-term effectiveness remains a mystery. Durations ranging from weeks to months [67,68]. The dose of 5 mL/kg of plasma at a titer of 1:160 was chosen based on prior experience with the use of convalescent plasma treatment in SARS [52].

CONCLUSION:

When conventional treatments, such as antiviral drugs or vaccinations, have failed to effectively combat a new or reemerging virus, CP offers a risk-free alternative. The mechanisms of action of IVIg and CP were quite similar. Currently, in COVID-19, CP's antiviral and immunomodulatory effects are being studied. In order to decrease mortality and enhance outcomes, COVID-19's pathophysiology suggests prioritizing severely ill patients above critically ill ones.

REFERENCES:

- [1]. Transfusion-transmitted infectious diseases: emerging and re-emerging infections: current views, Stramer SL. 2014, ISBT, Vol. 9, No. 1, pp. 30–6
- [2]. Research and Evaluation Center for Biologics. Emergency INDs due on 26 March 2020 for research on COVID-19 convalescent plasma. Investigative Covid-19 Convalescent Plasma Emergency Investigational Drugs are available at <https://www.fda.gov/vaccines-bloodbiologics/investigational-new-drug-ind-or-device-exemptionide-process-ber/>.
- [3]. A group of researchers led by Su et al. Pathogenesis, genetic recombination, and the spread of coronaviruses. *Microbiology Trends* 2016; 24:490-502.
<https://doi.org/10.1016/j.tim.2016.03.003> [4]. Infectious bronchitis caused by the coronavirus in birds. 2007 *Vet. Res.* 38:281-97.
<https://doi.org/10.1051/vetres:2006055>
- [5]. Research by Lu R, Zhao X, Li J, Niu P, Yang

B, Wu H, and others. Implications for viral origins and receptor binding from the genomic characterization and epidemiology of a new coronavirus in 2019. *Lancet* 2020; 395:3565-74. There is a DOI at [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8).

- [6]. Nie Q.-H., X.-D. Luo, and W.-L. Hui. Major progress in the clinical diagnosis and management of acute respiratory distress. 2003, Volume 9, Issue 9, Pages 1139–1143. The DOI is: 10.3748/wjg.v9.i6.1139.
- [7]. Authors: Zaki AM, S. van Boheemen, T.M. Bestebroer, A.D.M.E. Osterhaus, and R.A.M. Fouchier. Isolation

from a Saudi man with pneumonia, a previously unknown coronavirus. *The New England Journal of Medicine*.

Reference:

- <https://doi.org/10.1056/NEJMoa1211721>
- [8]. N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, and others. Pneumonia patients in China report a new coronavirus in 2019. A 2020 article in the *New England Journal of Medicine* will have the numbers 382.7:732.733. The online DOI is: 10.1056/NEJMoa2001017.
- [9]. Chu, H., Yang, J., Yuan, S., Kok, K.-H., To, K.-W., and Chan JF-W. Pneumonia in the family: a cluster analysis suggesting person-to-person spread of the 2019 new coronavirus. *Lancet* 2020; 395:514. Please cite this article as: [https://doi.org/10.1016/S0140-6736\(20\)30154-9](https://doi.org/10.1016/S0140-6736(20)30154-9).
- [10]. Collaborators: Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Patients in Wuhan, China, who were infected with a new coronavirus in 2019: clinical characteristics. *Lancet* 2020; 395:497–506. You may find the reference here: [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- [11]. Our role in COVID-19 pathophysiology, diagnosis, treatment, and vaccine design; Shoenfeld Y. *Corona (COVID-19) time reflections.* 2020 *Autoimmun Rev* 10:2538.
<https://doi.org/10.1016/j.autrev.2020.102538>
- [12]. Y. Shoenfeld and D. Kanduc. Understanding the molecular triggers and 2020 assault mechanism of SARS-CoV-2.

- Antibodies 2020, 21, 108426. Clin. Immunol. Reference: <https://doi.org/10.1016/j.clim.2020.108426> .1.
- Acosta-Ampudia Y, Rojas M, Restrepo-Jiménez P, Monsalve DM, Pacheco Y, Ramirez-Santana C, et al. Autoimmunity and molecular mimicry. 2018;95:100-23 J Autoimmun. <https://doi.org/10.1016/j.jaut.2018.10.012>. This was shown by Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Study evaluating the effectiveness of hydroxychloroquine in treating patients with COVID-19. It's time for MedRxiv 2020. To cite this article: <https://doi.org/10.1101/2020.03.22.20040758>.
- The group of Marano, Vaglio, Pupella, Facco, Catalano, Liunbruno, GM, and Liunbruno, GM, et al. The healing potential of convalescent plasma reexamined. Transfusions 2016; 14:152-7. <https://doi.org/10.2450/2015.0131-15>.
- Burnouf T, Seghatchian J (2016, p. Current status and potential future directions for Ebola virus convalescent blood products. 2014, Volume 51, Issue 1: Pages 120–5. Obtainable at: <http://dx.doi.org/10.1016/j.transci.2014.10.003>.
- The authors of this article (Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim WS, et al.) [17]. Treatment of severe acute respiratory infections due to viruses with convalescent plasma or hyperimmune immunoglobulin: a comprehensive review and exploratory meta-analysis. J Infect Dis. 211(2015):80-90. It may be found here: <https://doi.org/10.1093/infdis/jiu396>.
- Z. Shimoni, M. J. Niven, S. Pitlick, and S. Bulvik. [18]. Viral encephalitis caused by West Nile virus is treated with intravenous immunoglobulin. Publication date: 2001;7(7):759. Obtainable at: <https://doi.org/10.3201/eid0704.010432>.
- In [19], we have the following authors: van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. The effectiveness of Ebola virus illness convalescent plasma in Guinea is being evaluated. 2016;374(33-42)N. Engl. J. Med. <https://doi.org/10.1056/NEJMoa1511812>. The group included of O. Garraud, F. Heshmati, B. Pozzetto, L. Lefrere, R. Giroto, S. Saillol, A. et al. Infectious disease may now be treated with plasma today, tomorrow, and the day after that. 2016;23:39-44 Transfus Clin Biol. The citation is: <https://doi.org/10.1016/j.tracli.2015.12.003>.
- (Lünemann JD, Nimmerjahn F, Dalakas MC,) [21]. The mechanism of action and therapeutic use of intravenous immunoglobulin in neurological disorders. 2015, Vol. 11, No. 1, pp. 80–9. If you're interested, the DOI is 10.1038/nrneurol.2014.253.
- [22]. D. McGonagle, K. Sharif, A. McGonagle, and C. Bridgewood. Interleukin-6 and the COVID-19-induced pneumonia and macrophage activation syndrome-like disease: the involvement of cytokines. Rev Autoimmunity 2020. Check out this link: <https://doi.org/10.1016/j.autrev.2020.102537>. In press:102537.
- [23]. S. Wan, Q. Yi, F. Fan, J. Lv, X. Zhang, L. Guo, and S. Guo. Lymphocyte subset and cytokine profiles in peripheral blood from 123 individuals hospitalized with 2019 NCP. It's time for MedRxiv 2020. To cite this article: <https://doi.org/10.1101/2020.02.10.20021832>.
- [24]. Essay taking a stand on the topic of using recovered plasma, serum, or immune globulin concentrates in the face of a new virus. WHO Blood Regulators Network (BRN); 2017. <https://www.who.int/bloodproducts/brn/2017.pdf>. Geneva, Switzerland.
- 7_BRN_PositionPaper_ConvalescentPlasma.pdf?ua=1 15 May 2020 Access Date.
- [25]. Research by Bloch EM, Shoham S, Casadevall A, et al. Use of recovered plasma in COVID-19 prophylaxis and therapy. April 7, 2020; J. Clin. Invest. Specifically, [26] Pandey S, Vyas GN. Plasma transfusion side effects. 2012;52(Suppl 1):65S-79S in the journal Transfusion.
- [27]. Summary Report of the Transfusion-Related Injuries Surveillance System, 2011-2015, Volume 2020. Transfusion-Transmitted Injuries Surveillance System: 2011–2015 Summary Results. Ottawa (ON): Public

- Health Agency of Canada 2019. <https://www.canada.ca/en/publichealth/services/publications/drugs-health-products/>. As of May 22nd, 2020.
- TACO and TRALI: biology, risk factors, and preventative measures. [28] Roubinian, N. American Society of Hematology Educational Program for Hematologists. 2018.
- Transfusion-Associated Acute Lung Injury (TRALI) [29]; Petraszko, T. <https://professionaleducation.blood.ca/en/transfusion/publications/transfusion-related-acute-lung-injury-trali> (2019). Canadian Blood Services. 10 June, 2020 Access Date
- [30]. Those authors are: Casadevall A, LA Pirofski. COVID-19 may be contained with convalescent sera. 2020;130(4):1545-1548 in *J Clin Invest*.
- Molecular mechanism for antibody-dependent increase of Coronavirus penetration. [31] Wan Y, Shang J, Sun S, et al. Citation: *J Virol*. 2020;94(5):e02015-e02019.
- [32]. It was written by E.A. van Erp, W.L. Luytjes, G.F. Ferwerda, and P.B. van Kasteren. Respiratory syncytial virus infection and disease are accompanied by Fc-mediated antibody effector functions. *Immu. Front*. 2019; 10:548.
- [33]. Wec AZ, Herbert AS, Wec AZ, Brannan JM, Gunn BM, Yu WH, Karim MM, and others. Protecting against Ebola Virus with the Use of Therapeutic Monoclonal Antibodies: The Role of Fc Function. 2018 Feb;24(2):221-33.e5. *Cell Host Microbe*.
- [34]. L. Shahani, S. Singh, and N. M. Khardori. An overview of the development and use of immunotherapy in modern medicine. 96:421–431 (*Med Clin North Am* 2012) ix Obtainable at: <https://doi.org/10.1016/j.mcna.2012.04.001>.
- According to Shakir EM, DS Cheung, and MH Grayson [35]. Immunotherapy mechanisms: some background from the past. 105:340-7. quiz 348, 368. *Ann Allergy Asthma Immunol*, 2010. Obtainable at: <http://dx.doi.org/10.1016/j.anai.2010.09.012>.
- IVIG in autoimmunity and cancer: effectiveness vs safety. [36] Sherer Y, Levy Y, Shoenfeld Y. *Research in Drug Safety*. 2002, 1, 153-8. Expert Opinion on Drug Safety. Specifically: doi:10.1517/14740338.1.2.153.
- Katz, U., A. Achiron, Y. Sherer, and Y. Shoenfeld [37]. Immunoglobulin (IVIG) therapeutic safety. 2007;6:257-9. *Autoimmun Rev*. <https://doi.org/10.1016/j.autrev.2006.08.011>.
- For instance, see [38] by Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, et al. Two COVID-19 patients in Korea with acute respiratory distress syndrome were treated with convalescent plasma therapy. To Cite: *J Korean Med Sci*. 2020;35:e149. doi:10.3346/jkms.2020.35e149.
- Researchers J-H, Seok H, Cho SY, Ko Ha YE, Baek JY, Kim SH, and others [39]. Respiratory coronavirus infection in the Middle East: A single center's experience with the difficulties of convalescent plasma infusion treatment. *Virus Research* 2018; 23:617-22. Spalter SH, Kaveri S, Kazatchkine MD, [40] <https://doi.org/10.3851/IMP3243>. In typical polyspecific human IgG (intravenous immunoglobulin, IVIG) therapeutic preparations, anti-idiotypes to autoantibodies are present. *Infection and Cancer SBT-I in MAeditors: Shoenfeld Y, Kennedy RC, Ferrone. Medical autoimmune infectious cancer phenotypes Elsevier: Amsterdam, 1997, pp. 217–25.* <https://doi.org/10.1016/B978-044482807-1/50021-1>.
- [41]. Researchers Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. COVID-19 patients in Wuhan, China get treatment using convalescent plasma. 2020 *Journal of Medical Virology*. This article's DOI is <https://doi.org/10.1002/jmv.25882>.
- This was shown by Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Covid-19 convalescent plasma for the treatment of 5 severely sick patients. *JAMA* 2020;323(16):1582–9. <https://doi.org/10.1001/jama.2020.4783>
- [43]. This includes Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, and others. Recovery from severe COVID-19 with convalescent plasma treatment.